Ellevest Inc’s Summit Therapeutics SMMT Stock Holding History

Ellevest Inc’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-36	Closed	–	–	1844
2022 Q2	$0	Hold	36	–	–	﹤0.01%	1661
2022 Q1	$0	Buy	+36	New	+$91	﹤0.01%	1617

Other funds holding SMMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ellevest Inc's SMMT Position: Q3 2022 in Review

Ellevest Inc sold out of Summit Therapeutics (SMMT) in Q3 2022, closing a stake of 36 shares.

Ellevest Inc first reported a position in SMMT in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 45 funds tracked by Wall St. Rank hold SMMT as of Q3 2022.

Ellevest Inc reported no remaining Summit Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 36 Summit Therapeutics shares in Q3 2022.
Ellevest Inc first reported a position in Summit Therapeutics in Q1 2022 and held it in 2 quarters.
Ellevest Inc's Summit Therapeutics position peaked at $0 in Q2 2022.
45 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.